Ophthalmology Department, Shamir Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eye (Lond). 2023 Apr;37(6):1219-1224. doi: 10.1038/s41433-022-02093-4. Epub 2022 May 19.
Standard corneal collagen cross-linking (S-CXL) is an effective treatment to arrest Keratoconus (KC) progression in children. Less is known on the long-term efficacy of accelerated CXL (A-CXL) in paediatric populations.
A historical cohort analysis of paediatric patients (≤18 years) with KC who underwent S-CXL and A-CXL at two tertiary referral centres in Israel between 2010-2017. Preoperative and 3-year postoperative evaluation included changes in visual acuity (best spectacle corrected [BSCVA]) and uncorrected [UCVA]), refractive errors, and keratometric data.
Ninety-three eyes of 93 patients were analysed (A-CXL: n = 39; S-CXL: n = 54). Baseline characteristics were similar between groups. Both groups showed a significant improvement in visual acuity compared to baseline (S-CXL: 0.810-0.602 LogMAR UCVA; A-CXL: 0.890-0.306 LogMAR UCVA, p < 0.05 for both). Improvement in BSCVA and UCVA following A-CXL was non-inferior to S-CXL (< ± 0.2 LogMAR). Kmax decreased by a mean of 0.98 ± 5.56 dioptres following S-CXL (p = 0.02) and by 1.48 ± 8.4 dioptres following A-CXL (p = 0.015). Thinnest pachymetry decreased following both treatments (S-CXL: by 26.8 ± 40.7 µm, p = 0.001, A-CXL: by 10.2 ± 13.4 µm, p = 0.028), the difference between groups was within the non-inferiority margin (< ± 10 µm).
Paediatric patients followed for three years after A-CXL showed improved visual function, reduced corneal astigmatism and Kmax, and decreased thinnest corneal thickness. A-CXL was non-inferior to S-CXL at three years in terms of best-corrected and uncorrected visual acuity, thinnest pachymetry, and astigmatism. For Kmax, non-inferiority could not be concluded.
标准角膜胶原交联术(S-CXL)是一种有效治疗儿童圆锥角膜(KC)进展的方法。对于加速 CXL(A-CXL)在儿科人群中的长期疗效知之甚少。
这是一项在以色列两个三级转诊中心进行的回顾性队列研究,纳入了 2010 年至 2017 年期间接受 S-CXL 和 A-CXL 治疗的 KC 儿童患者(≤18 岁)。术前和 3 年的术后评估包括视力(最佳矫正视力 [BSCVA] 和未矫正视力 [UCVA])、屈光不正和角膜曲率数据的变化。
共分析了 93 例 93 只眼(A-CXL:n=39;S-CXL:n=54)。两组间基线特征相似。与基线相比,两组的视力均有显著改善(S-CXL:0.810-0.602 LogMAR UCVA;A-CXL:0.890-0.306 LogMAR UCVA,均<0.05)。A-CXL 后 BSCVA 和 UCVA 的改善与 S-CXL 相当(<±0.2 LogMAR)。与 S-CXL 相比,A-CXL 后 Kmax 降低了 0.98±5.56 屈光度(p=0.02),降低了 1.48±8.4 屈光度(p=0.015)。两种治疗方法后角膜最薄厚度均降低(S-CXL:减少 26.8±40.7μm,p=0.001,A-CXL:减少 10.2±13.4μm,p=0.028),组间差异在非劣效性范围内(<±10μm)。
A-CXL 治疗后随访 3 年的儿童患者,视力功能提高,角膜散光和 Kmax 降低,角膜最薄厚度减少。在最佳矫正和未矫正视力、角膜最薄厚度和散光方面,A-CXL 与 S-CXL 在 3 年时无差异。对于 Kmax,无法得出非劣效性结论。